PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.

被引：6
|
作者：
Pascual, Javier
MacPherson, Iain R.
Armstrong, Anne Caroline
Ward, Sarah Emily
Parmar, Mona
Turner, Alison Joanne
Bye, Hannah
Proszek, Paula
Dodson, Andrew
Garcia-Murillas, Isaac
King, Jenny
Hall, Emma
Finneran, Laura
Lopez, Juanita Suzanne
Okines, Alicia Frances Clare
Ring, Alistair E.
Turner, Nicholas C.
机构：
[1] Royal Marsden Hosp, London, England
[2] Inst Canc Res, London, England
[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[5] Inst Canc Res, Sutton, Surrey, England
[6] Royal Marsden Inst Canc Res, London, England
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Inst Canc Res, Clin Trials & Stat Unit, London, England
[9] Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1051
引用
收藏
页数：2
相关论文
共 46 条
  • [1] Triplet Therapy with Palbociclib, Taselisib, and fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
    Pascual, Javier
    Lim, Joline S. J.
    Macpherson, Iain R.
    Armstrong, Anne C.
    Ring, Alistair
    Okines, Alicia F. C.
    Cutts, Rosalind J.
    Herrera-Abreu, Maria Teresa
    Garcia-Murillas, Isaac
    Pearson, Alex
    Hrebien, Sarah
    Gevensleben, Heidrun
    Proszek, Paula Z.
    Hubank, Michael
    Hills, Margaret
    King, Jenny
    Parmar, Mona
    Prout, Toby
    Finneran, Laura
    Malia, Jason
    Swales, Karen E.
    Ruddle, Ruth
    Raynaud, Florence, I
    Turner, Alison
    Hall, Emma
    Yap, Timothy A.
    Lopez, Juanita S.
    Turner, Nicholas C.
    CANCER DISCOVERY, 2021, 11 (01) : 92 - 107
  • [2] Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
    Jhaveri, Komal
    Chang, Matthew T.
    Juric, Dejan
    Saura, Cristina
    Gambardella, Valentina
    Melnyk, Anton
    Patel, Manish R.
    Ribrag, Vincent
    Ma, Cynthia X.
    Aljumaily, Raid
    Bedard, Philippe L.
    Sachdev, Jasgit C.
    Dunn, Lara
    Won, Helen
    Bond, John
    Jones, Surai
    Savage, Heidi M.
    Scaltriti, Maurizio
    Wilson, Timothy R.
    Wei, Michael C.
    Hyman, David M.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 447 - 459
  • [3] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours
    Baselga, J.
    Cortes Castan, J.
    De Laurentiis, M.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H.
    Jacot, W.
    Krop, I. E.
    Verma, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors
    Baselga, Jose
    Cortes, Javier
    DeLaurentils, Michelino
    Dent, Susan
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Jin, Huan
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
    Baselga, Jose
    Cortes, Javier
    De Laurentiis, Michele
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Ng, Vivian
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Dent, S.
    Cortes, J.
    Im, Y-H
    Dieras, V
    Harbeck, N.
    Krop, I. E.
    Wilson, T. R.
    Cui, N.
    Schimmoller, F.
    Hsu, J. Y.
    He, J.
    De Laurentiis, M.
    Sousa, S.
    Drullinsky, P.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 197 - 207
  • [7] PIPA: A phase Ib study of selective β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers-Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
    Lopez, Juanita Suzanne
    SelviMiralles, Manuel
    Ameratunga, Malaka
    Minchom, Anna
    Pascual, Javier
    Banerji, Udai
    Bye, Hannah
    Raynaud, Florence I.
    Swales, Karen E.
    Malia, Jason
    Hubank, Michael
    Garcia-Murillas, Isaac
    Parmar, Mona
    Ward, Sarah Emily
    Finneran, Laura
    Hall, Emma
    Turner, Alison Joanne
    De Bono, Johann S.
    Yap, Timothy A.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Baselga, J.
    Cortes, J.
    De Laurentiis, M.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H
    Jacot, W.
    Krop, I. E.
    Verma, S.
    CANCER RESEARCH, 2016, 76
  • [9] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Baselga, J.
    Cortes, J.
    De laurentiis, M.
    Dent, S.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H
    Jacot, W.
    Krop, I. E.
    Verma, S.
    CANCER RESEARCH, 2017, 77
  • [10] Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
    Moein, Anita
    Jin, Jin Y.
    Wright, Matthew R.
    Wong, Harvey
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 421 - 436
12345